Furfurman as a Vaccine Adjuvant for Foot-and-Mouth Disease
Author Information
Author(s): Kim Hyeong Won, Shin Seokwon, Park So Hui, Park Jong-Hyeon, Kim Su-Mi, Lee Yoon-Hee, Lee Min Ja
Primary Institution: Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si, Gyeongsangbuk-do, Republic of Korea
Hypothesis
An advanced FMD vaccine that uses furfurman as an adjuvant could address the shortcomings of commercial vaccines.
Conclusion
The study demonstrated that furfurman, as an FMD vaccine adjuvant, achieves long-lasting immunity and host defense against viral infections.
Supporting Evidence
- The groups that received the vaccine containing furfurman showed a strong immune response compared to control groups.
- The significant upregulation of cytokine levels in the furfurman group suggests enhanced immune response.
- The test vaccine elicited a robust host defense against FMDV infection during early, mid-term, and long-term periods.
- Furfurman stimulated the proliferation of immune cells within 24 hours after vaccination.
- The Exp group maintained significant antibody and VN titers compared to the PC group until 168 dpv.
Takeaway
This study shows that a new vaccine with furfurman helps animals fight off foot-and-mouth disease better and for a longer time.
Methodology
The efficacy of the test vaccine was evaluated by measuring antibody and neutralizing antibody titers and host defense against viral infections in experimental animals.
Limitations
Only a few cytokines were measured within a narrow vaccination period, and the signaling pathways induced by furfurman were not revealed.
Participant Demographics
Mice (C57BL/6, 6–7 weeks old, female) and farm pigs (Landrace; 8–9 weeks old).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website